BACKGROUND Controversy exists concerning the need for aspiration before injection with hyaluronic acid (HA) fillers.
C ontroversy exists concerning the need for aspiration before injection with hyaluronic acid (HA) fillers. Traditionally, before any injection into the body, 2 principles regularly taught are removal of air from the syringe by priming or filling the needle with the solution and withdrawing the plunger in vivo before injection to ensure that the needle is not intravascular. 1 Typically, the injected material is an aqueous type of solution with similar characteristics and flow comparable with blood. Withdrawal of the plunger would easily draw back the solution into the syringe and allow blood to enter the syringe if the needle was located in the lumen of a vessel. However, HA fillers used for cosmetic procedures have a gel-like consistency which do not have the same flow parameters of a liquid, and may impede the flow of blood back into the syringe. A negative pull test by retraction of the plunger before injection using these products may give a false sense of security that the needle is extravascular.
The authors undertook a study of HA products obtained from 4 of the major manufacturers to determine if blood could be aspirated back into a syringe of HA when the needle has been filled with HA. The authors examined all available HA products of each company to study these findings.
The authors used a series of different gauge needles of the same length on all products except for 2 companies where additionally the authors used their supplied 29 G 1$ needle and 25 G 1$ needle. Two different techniques were tested; one using a slow-pull retraction of the plunger and up to a 5 seconds waiting time versus a rapid pullback and quick release, which represents more accurately the technique used in clinical practice. This was performed on each product using needles with increasing diameter until blood was aspirated.
Overall their findings suggest that for the majority of the products particularly with a high G prime and high cohesivity that retraction of the plunger when using primed smaller gauge needles or needles presupplied with product do not allow for clearing of gel in the needle lumen or hub. Subsequently, entry of blood into the syringe is blocked, particularly when using a rapidpull release method. Therefore, the concept of being extravascular while injecting HA cannot be determined in most cases by aspiration before injection. The importance of these findings is applicable mainly for bolus injections where the needle is held in a stationary position.
Also with the increased use of motorized injectable devices that do not allow for the retraction of the plunger before injection, these results are relevant in determining their safety compared with the manual method.
Methods
In vivo and in vitro experiments were done to determine the smallest needle caliber through which blood could be aspirated into an empty syringe without HA present either in the needle or in the syringe.
Next, an in vitro study was performed to determine where the potential blockage to aspiration of blood could occur. Initially syringes of filler with the needle loaded with HA were used in an attempt to obtain blood from a heparinized tube of blood. If the authors were unable to withdraw blood, the primed needle was removed from that particular syringe and an empty needle of the same caliber devoid of HA was attached and reinserted into the tube to determine if blood could be withdrawn into the syringe.
Subsequently, 2 studies were set up to determine if or when blood could be withdrawn from a heparinized fresh tube of blood into the HA syringe. The authors used a series of increasing diameter needles until blood was obtained. The authors studied the complete product lines of 4 HA manufacturers, Teoxane, Merz, Galderma/Medicis, and Allergan. Some lines were not available in the United States and were studied only by the lead author.
All needles were primed with HA before withdrawing. A series of needles were used starting with the company-supplied 30 G, 29 G(Medicis only), 27 G, company-supplied 27 G (larger lumen), and finally 25 G and 25 G(Teoxane supplied). The productspecific needle supplied in the box was always used for the tested material and is indicated in the chart (Tables  1 and 2 indicated in red).
For the first technique, the slow pullback and hold method (Table 1 ), 0.6 mL of material was initially extruded and discarded from the 1 mL syringes or 1.6 mL in the 2 mL syringes. This was to allow sufficient space to pullback the plunger to a maximum of 0.8 mL (0.4 mL of product and 0.4 of empty space) to create a significant negative pressure estimated to be 0.5 atm.
With 0.4 mL of HA material left in the syringe, initially a 30 G needle was primed with the tested HA before insertion of the needle through the rubber stopper of the tube containing heparinized blood. The tube was held at approximately a 20°incline.
First, the authors determined what the smallest caliber of needle was through which blood could be aspirated into the tested syringe. If no blood was withdrawn, the needle was changed up to the next larger diameter and a small amount of material was extruded again to prime or fill the needle. The systematic increase in the needle caliber was continued until blood was withdrawn into the syringe.
For the first technique of slow pullback, the plunger was retracted very slowly using approximately 10 seconds to reach the 0.8 mL marking of the syringe if needed representing a negative pressure of 0.4 mL. The plunger was also retained in place up to a maximum of 5 seconds before release. The negative pressure was noted in mL if blood entered the syringe during the retraction period before reaching the 0.8 mL mark.
The second technique was used to replicate the usual clinical technique used by many of the injectors who perform a rapid pullback before injection ( Table 2 ). The plunger was pulled back promptly and then released using the thumb of the injecting hand, as often the nondominant hand is used to hold the skin tight and may not be available to withdraw on the plunger. The syringes were loaded in the same manner as in the slow pullback technique and the needles were similarly systematically exchanged using larger calibers until blood was obtained. The 0.4 mL and hold indicates that during the 5 seconds hold period at 0.4 mL retraction that blood was obtained (0.4 mL of product and 0.4 mL empty space).
The mL indicates, for example that the plunger went from the initial 0.4 mL to 0.6 mL marking before blood was seen in the syringe (i.e., marked 0.2 mL).
N/A-the material was not tested with the needle; neg signifies that no blood was obtained in the syringe after retracting plunger another 0.4 mL and holding for 5 seconds before releasing the plunger. If blood was observed in the syringe no further testing was done on larger diameter needles unless the company supplied needle had not been tested.
Results
Using an empty syringe and a needle free of HA it is easy to withdraw blood in vivo from a vein or in vitro from a tube containing heparinized blood, even with a 32 G needle. As the gauge increases so does the flow rate into the syringe.
In vivo, too strong of a negative pressure created by rapid or excessive pulling back of the plunger can collapse a small vein preventing withdrawal of blood. This phenomenon is less likely to occur in an artery.
Because a greater pressure gradient is required for gels compared with water (saline) (oral communi- N/A-the material was not tested with the needle. Neg signifies that no blood was obtained in the syringe after retracting the plunger rapidly 0.4 ml and releasing immediately the plunger. The mL signifies the amount of retraction before blood was obtained in the syringe.
but firm withdrawal of the plunger in a linear nonaccelerated manner is essential if the practitioner is attempting to check for intravascular placement of the needle.
In vitro, when withdrawal test brings back no blood from the test tube, by replacing the HA-loaded needle with a HA-free needle of the same gauge or even smaller, one can then readily withdraw blood into the HA-containing syringe in all cases. This clearly demonstrates that the ability to withdraw blood into the syringe requires the needle lumen or hub to be cleared of HA. The viscosity of blood or the material in the syringe itself plays no role.
Factors affecting the removal of HA from the needle will be the consistency and cohesivity of the material, length of the needle, force of suction applied, and the time under negative pressure during withdrawal. Theoretically, products that are less cohesive and or having a low G prime would likely be released from the needle more easily as seen in this study.
2,3
Review of these data also demonstrates that the usual clinical technique, which involves pulling back quickly with a short wait time before release, in most cases does not allow for sufficient removal of the intraluminal filler, leading to false negative results in vitro and likely in vivo.
Using a slower withdrawal rate then holding the syringe under a negative pressure for up to 5 seconds demonstrates that there is variability between different product lines and different companies. There were also more positive results when comparing the same product and needle size from this technique with the rapid pull and release method. The products that are cleared intraluminally consistently on the slow-pull test are the products from Galderma/Medicis when using only their supplied needles. Despite having a high G prime, this product also has a low cohesive value. 2 On the rapid pull test, it was negative only for Perlane.
Using a manual retraction method, certain variables could not be controlled such as a uniform retraction pressure on each syringe but the findings suggest that for the majority of the products particularly with a high G prime and cohesivity, retraction of the plunger when using smaller gauge needles or those supplied with the particular product do not allow for cleansing of the needle lumen or hub and thus subsequent entry of blood into the syringe, particularly when using a rapid pull release method.
Discussion
Intraarterial or intravenous injection of HA is an undesirable side effect with the former having more serious consequences. Although not frequent, the results of vascular occlusion also known as Nicolau syndrome can result in necrosis, scarring and morbidity, blindness, or less commonly ischemic cerebral accidents. 4 A number of procedures and treatments have been described previously to deal with this medical emergency. 4, 5 This may occur more commonly in areas having had previous surgery because the vessels are less mobile and more susceptible to puncture.
There are conflicting reports on preventing intravascular injections. Many authors have recommended withdrawal of the plunger before injection, the use of cannulas only, using small bore needles, using large bore needles, concomitant use or the absence of lidocaine containing epinephrine, injecting a small bolus at multiple sites, injecting slowly, pinching the tissue before injection, compression, or limitation of volume. [4] [5] [6] Despite the technique used, from the experience of the injector or precautions taken, an intravascular injection may occur.
The authors took a particular interest in studying the dynamics of plunger withdrawal before injection. Both authors prefer using needles and do not aspirate before injecting HA syringes. This method is done or recommended routinely but it is not evidence based but rather on an historic adage, it is important to withdraw the plunger before injecting.
The studies performed demonstrated clearly that to be 100% certain that blood is pulled back successfully if the needle or cannula was intravascular would be to change the needle each time one injected a bolus with a HA-free nonprimed needle. This method, however, would be impractical, create a significant loss of product in the dead space of the discarded needle with each injection, with also the potential risk of an air embolus because the empty needle contains air.
The results show that withdrawal in most cases fails to clear the needle lumen of material allowing return of blood, particularly with the rapid pull-release method. Whether material remains in the narrow lumen or congests the needle hub or both is not certain. The more efficacious technique of the 2 methods to withdraw blood is to maintain a maximum negative pressure with a prolonged waiting period, which may release the material. However, this would be impractical, and not always a certainty. Certain product lines and certain companies have products, which are more likely to block the needle. The Galderma/Medicis products routinely are cleared from the needle using the slow-pull technique.
The rapid pull and release technique is significantly less effective in demonstrating blood withdrawal, especially with cohesive HA materials. Company supplied needles, which are usually of a smaller caliber will impede blood return. Another factor complicating this maneuver is that with a full syringe of HA less negative pressure can be achieved with retraction of the plunger. Not all companies have their plungers screwed into the mobile rubber tip and the plunger can be easily pulled off this on retraction of the plunger. The other point to be made is that it is unlikely with the maneuvers required to pullback and release a viscous gel that the needle remains absolutely in the exact same cutaneous position during the withdrawal and release of the syringe plunger.
Certain areas may be more prone to inadvertent intravascular injections or more susceptible to damage due to lack of collateral circulation. 6 The cutaneous tissue in the region of the superior nasolabial line lateral to the nose at the site of the lateral nasal branch of the angular artery is extremely fibrous and adherent possibly preventing vessels to be pushed out of the way with an advancing needle or small cannulas, as may occur in scar tissue. In contrast, certain areas sometimes labeled as dangerous such as the infraorbital artery/vein location 7 are relatively comparatively safe due to an extensive collateral circulation. 8 It has been postulated that certain types of HA may elicit more damage than others depending on their rheological properties. 4 The quantity of material will likely affect the outcome. Usually more than 0.1 mL needs to be injected intraarterially to cause significant injury likely due to collateral vessels except in a few specific areas such as the retina. Therefore a slow, prudent "stop and go" technique should limit damage. In most cases an embolization can be recognized immediately, by an immediate whitening of the skin, and subsequent bluish hue. Therefore, injecting rapidly under high pressure may result in larger amounts delivered intravascularly before action can be taken to stop the injection.
From these data, the controversy surrounding the safety of motorized delivery equipment such as the Teosyal Pen, AIS, and The Artist (Figure 1 ), which do not allow for retraction of the plunger, is negated. Because they have as a feature, a controllable flow rate, and continuous low pressure that can be even delivered in drops, there may be reduction in injection risks. Motorized devices may also offer some advantages whereby multiple controlled micro boluses can be delivered, particularly in danger zones such as the nose. It may allow the physician to maintain their concentration on observing the patient without having to concentrate on the injecting hand and the volume delivered. 9 Many of the cases of embolism recorded were in situations where the material was being injected under high pressure. 4 More case studies will be required to document this decreased risk using motorized injectable devices.
In summary, one cannot document negative intravascular position with a negative pullback of the plunger. Certain maneuvers such as compressing, tenting, pinching, and slow injections may diminish the risk or the degree of damage if it occurs. One author suggests limiting the injection flow to 0.3 mL/ min. 7 The authors agree and suggest an even longer injection duration of 2 minutes per 0.3 mL, particularly when injecting in susceptible areas. For physicians who wish to continue using a pullback technique before injection, the authors can only recommend using a large bore needle, maximum negative pressure, fixation of the syringe position, and extended waiting time while the syringe is under negative pressure.
